Skip to main content
SpringerLink
Log in

Expression of P-glycoprotein in lymphocytes from children with nephrotic syndrome, depending on their steroid response

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

The aim of this study was to examine the expression of P-glycoprotein (P-gp) in CD3 lymphocytes of children with nephrotic syndrome (NS) in relation to their clinical response to glucocorticoid (GC) treatment. The examinations were performed on two groups. The study group (I) consisted of 88 children aged 2.0–20.0 years with NS, divided according to their clinical response to GC: NFR—non-frequent relapse NS; FR—frequent relapse NS; SD—steroid-dependent NS. The control group (II) consisted of 18 healthy children never treated with GC. We measured P-gp expression on CD3 lymphocytes of patients with NS using a flow cytometry assay. The CD3/P-gp was significantly higher than in controls. The difference was higher in SD (P=0.0001) and FR - (P=0.0002) group. The difference in NFR was smaller. Mean CD3/P-gp (in percent) was twice as high in SD children than in NFR, and the difference, as between FR and NFR, was statistically significant (P<0.01). Worse response to GC or dependency may be due to overexpression of P-gp. Further examinations are necessary to establish whether increased P-gp activity is a result of MDR-1 polymorphism and to determine GC response, or to ascertain if such activity is only a result of GC therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Nasi M, Aedelmann CM, Berstein J, Barnett HL (1992) The nephrotic syndrome. In: Edelmann CM, Berstein J, Meadow SR, Spitzer A, Travis LB (eds) Pediatric kidney disease, vol 2. Little, Brown, Boston, pp 1247–1266

    Google Scholar 

  2. No authors listed (1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 98:561–564

    Google Scholar 

  3. Ehrich JH, Brodehl J (1993) Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Eur J Pediatr 152:357–361

    Article  PubMed  CAS  Google Scholar 

  4. Leung DJ, Bloom JW (2003) Update on glucocorticoid action and resistance. J Allergy Clin Immunol 111:3–22

    Article  PubMed  CAS  Google Scholar 

  5. Hearing SD, Norman M, Probert CS, Haslam N, Dayan CM (1999) Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 45:382–388

    Article  PubMed  CAS  Google Scholar 

  6. Lane SJ, Lee TH (1996) Corticosteroid resistance in other disease states and tissues. Am J Respir Crit Care Med 154:S62–S65

    PubMed  CAS  Google Scholar 

  7. Ling V (1997) Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40 [Suppl]:S3–S8

    Article  PubMed  CAS  Google Scholar 

  8. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162

    Article  PubMed  CAS  Google Scholar 

  9. Klimecki WT, Futscher BW, Grogan TM, Dalton WS (1994) P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83:2451–2458

    PubMed  CAS  Google Scholar 

  10. Ford JM (1995) Modulators of multidrug resistance. Preclinical studies. Hematol Oncol Clin North Am 9:337–361

    PubMed  CAS  Google Scholar 

  11. No authors listed (1982) Early identification of frequent relapsers among children with minimal change nephrotic syndrome. A report of the international study of kidney disease in children. J Pediatr 101:514–518

    Google Scholar 

  12. No authors listed (1987) Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie. Arch Dis Child 62:1102–1106

    Google Scholar 

  13. List AF, Kopecky KJ, Willman CL, Head DR, Slovak ML, Douer D, Dakhil SR, Appelbaum FR (2002) Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. Blood 100:1910–1912

    PubMed  CAS  Google Scholar 

  14. Siiteri PK, Murai JT, Hammond GL, Nisker JA, Raymoure WJ, Kuhn RW (1982) The serum transport of steroid hormones. Recent Prog Horm Res 38:457–510

    PubMed  CAS  Google Scholar 

  15. Beck WT, Grogan TM (1997) Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins. Leukemia 11:1107–1109

    Article  PubMed  CAS  Google Scholar 

  16. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tsukada J, Kohno K, Tanaka Y (2004) Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. Genes Cells 9:1265–1273

    Article  PubMed  CAS  Google Scholar 

  17. Tsuruo T (1983) Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. Cancer Treat Rep 67:889–894

    PubMed  CAS  Google Scholar 

  18. Bourgeois S, Gruol DJ, Newby RF, Rajah FM (1993) Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol Endocrinol 7:840–851

    Article  PubMed  CAS  Google Scholar 

  19. Meijer OC, de Lange EC, Breimer DD, de Boer AG, Workel JO, de Kloet ER (1998) Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 139:1789–1793

    Article  PubMed  CAS  Google Scholar 

  20. Inoue Y, Iijima K, Nakamura H, Yoshikawa N (1999) Two-year cyclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 13:33–38

    Article  PubMed  CAS  Google Scholar 

  21. Farrell RJ, Kelleher D (2003) Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 178:339–346

    Article  PubMed  CAS  Google Scholar 

  22. Montano E, Schmitz M, Blaser K, Simon HU (1996) P-glycoprotein expression in circulating blood leukocytes of patients with steroid-resistant asthma. J Investig Allergol Clin Immunol 6:14–21

    PubMed  CAS  Google Scholar 

  23. Szefler SJ (1991) Glucocorticoid therapy for asthma: clinical pharmacology. J Allergy Clin Immunol 88:147–165

    Article  PubMed  CAS  Google Scholar 

  24. Wasilewska A, Zoch-Zwierz W, Pietruczuk M (2006) Expression of P-glycoprotein in lymphocytes of children with nephrotic syndrome treated with glucocorticoids. Eur J Pediatr (in press)

  25. Ruiz-Soto R, Richaud-Patin Y, Lopez-Karpovitch X, Llorente L (2003) Multidrug resistance-1 (MDR-1) in autoimmune disorders III: increased P-glycoprotein activity in lymphocytes from immune thrombocytopenic purpura patients. Exp Hematol 31:483–487

    Article  PubMed  CAS  Google Scholar 

  26. Diaz-Borjon A, Richaud-Patin Y, Alvarado de la Barrera C, Jakez-Ocampo J, Ruiz-Arguelles A, Llorente L (2000) Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II: increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control. Joint Bone Spine 67:40–48

    PubMed  CAS  Google Scholar 

  27. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y (2005) Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis Rheum 52:1676–1683

    Article  PubMed  CAS  Google Scholar 

  28. Maillefert JF, Maynadie M, Tebib JG, Aho S, Walker P, Chatard C, Dulieu V, Bouvier M, Carli PM, Tavernier C (1996) Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol 35:430–435

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1st Department of Pediatrics, Medical University of Białystok, ul. Waszyngtona 17, 15-274, Białystok, Poland

    Anna Wasilewska, Walentyna Zoch-Zwierz & Grzegorz Zalewski

  2. Department of Haematological Diagnostics, Medical University of Białystok, Białystok, Poland

    Miroslawa Pietruczuk

Authors
  1. Anna Wasilewska
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Walentyna Zoch-Zwierz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miroslawa Pietruczuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Grzegorz Zalewski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna Wasilewska.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wasilewska, A., Zoch-Zwierz, W., Pietruczuk, M. et al. Expression of P-glycoprotein in lymphocytes from children with nephrotic syndrome, depending on their steroid response. Pediatr Nephrol 21, 1274–1280 (2006). https://doi.org/10.1007/s00467-006-0187-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-006-0187-2

Keywords

Search

Navigation